GLP-1 receptor agonists in Parkinson's disease progression: a meta-analysis with trial sequential analysis of randomized controlled trials.

Ther Adv Neurol Disord · 2025 · PMC12426393 · PMID 40951542

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

A nonsignificant trend toward increased serious adverse events or treatment discontinuation was observed (odds ratio = 1.52; 95% CI: 0.66; 3.50), with low heterogeneity.

also in 5,406 other papers

did not reach statistical significanceno p-value reported

The group receiving GLP-1 RAs demonstrated a slightly slower progression in MDS-UPDRS Part III (on medication) compared to the control group (MD = −1.64, 95% CI (−4.30; 1.03)) with considerable heterogeneity ( I 2 = 68%), but the difference did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.